Cargando…

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

BACKGROUND: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. METHODS: EGFR status was analyzed by immunohistochemistry (...

Descripción completa

Detalles Bibliográficos
Autores principales: Atmaca, Akin, Werner, Dominique, Pauligk, Claudia, Steinmetz, Kristina, Wirtz, Ralph, Altmannsberger, Hans-Michael, Jäger, Elke, Al-Batran, Salah-Eddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529672/
https://www.ncbi.nlm.nih.gov/pubmed/23153332
http://dx.doi.org/10.1186/1471-2407-12-524
_version_ 1782253941585608704
author Atmaca, Akin
Werner, Dominique
Pauligk, Claudia
Steinmetz, Kristina
Wirtz, Ralph
Altmannsberger, Hans-Michael
Jäger, Elke
Al-Batran, Salah-Eddin
author_facet Atmaca, Akin
Werner, Dominique
Pauligk, Claudia
Steinmetz, Kristina
Wirtz, Ralph
Altmannsberger, Hans-Michael
Jäger, Elke
Al-Batran, Salah-Eddin
author_sort Atmaca, Akin
collection PubMed
description BACKGROUND: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. METHODS: EGFR status was analyzed by immunohistochemistry (IHC) in paraffin-embedded samples from 357 patients who received chemotherapy in 4 first-line trials. Automated RNA extraction from paraffin and RT-quantitative PCR were additionally used to evaluate EGFR mRNA expression in 130 patients. RESULTS: EGFR protein expression (any grade) and overexpression (3+) were observed in 43% and 11% of patients, respectively. EGFR positivity correlated with intestinal type histology (p = 0.05), but not with other clinicopathologic characteristics. Median follow-up was 18.2 months. Median overall survival (OS) was similar in patients with EGFR positive vs. those with EGFR negative tumors, regardless whether positivity was defined as ≥1+ (10.6 vs. 10.9 months, p = 0.463) or as 3+ (8.6 vs. 10.8 months, p = 0.377). The multivariate analysis indicated that EGFR status is not an independent prognostic factor (hazard ratio 0.85, 0.56 to 1.12, p = 0.247). There were also no significant differences in overall survival when patients were categorized according to median (p = 0.116) or quartile (p = 0.767) distribution of EGFR mRNA gene expression. Similar distributions of progression-free survival according to EGFR status were observed. CONCLUSIONS: Unlike different cancer types where EGFR-positive disease is associated with an adverse prognostic value, EGFR positivity is not prognostic of patient outcome in metastatic gastric or GE cancer.
format Online
Article
Text
id pubmed-3529672
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35296722013-01-03 The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer Atmaca, Akin Werner, Dominique Pauligk, Claudia Steinmetz, Kristina Wirtz, Ralph Altmannsberger, Hans-Michael Jäger, Elke Al-Batran, Salah-Eddin BMC Cancer Research Article BACKGROUND: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. METHODS: EGFR status was analyzed by immunohistochemistry (IHC) in paraffin-embedded samples from 357 patients who received chemotherapy in 4 first-line trials. Automated RNA extraction from paraffin and RT-quantitative PCR were additionally used to evaluate EGFR mRNA expression in 130 patients. RESULTS: EGFR protein expression (any grade) and overexpression (3+) were observed in 43% and 11% of patients, respectively. EGFR positivity correlated with intestinal type histology (p = 0.05), but not with other clinicopathologic characteristics. Median follow-up was 18.2 months. Median overall survival (OS) was similar in patients with EGFR positive vs. those with EGFR negative tumors, regardless whether positivity was defined as ≥1+ (10.6 vs. 10.9 months, p = 0.463) or as 3+ (8.6 vs. 10.8 months, p = 0.377). The multivariate analysis indicated that EGFR status is not an independent prognostic factor (hazard ratio 0.85, 0.56 to 1.12, p = 0.247). There were also no significant differences in overall survival when patients were categorized according to median (p = 0.116) or quartile (p = 0.767) distribution of EGFR mRNA gene expression. Similar distributions of progression-free survival according to EGFR status were observed. CONCLUSIONS: Unlike different cancer types where EGFR-positive disease is associated with an adverse prognostic value, EGFR positivity is not prognostic of patient outcome in metastatic gastric or GE cancer. BioMed Central 2012-11-15 /pmc/articles/PMC3529672/ /pubmed/23153332 http://dx.doi.org/10.1186/1471-2407-12-524 Text en Copyright ©2012 Atmaca et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Atmaca, Akin
Werner, Dominique
Pauligk, Claudia
Steinmetz, Kristina
Wirtz, Ralph
Altmannsberger, Hans-Michael
Jäger, Elke
Al-Batran, Salah-Eddin
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
title The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
title_full The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
title_fullStr The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
title_full_unstemmed The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
title_short The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
title_sort prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529672/
https://www.ncbi.nlm.nih.gov/pubmed/23153332
http://dx.doi.org/10.1186/1471-2407-12-524
work_keys_str_mv AT atmacaakin theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT wernerdominique theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT pauligkclaudia theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT steinmetzkristina theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT wirtzralph theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT altmannsbergerhansmichael theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT jagerelke theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT albatransalaheddin theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT atmacaakin prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT wernerdominique prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT pauligkclaudia prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT steinmetzkristina prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT wirtzralph prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT altmannsbergerhansmichael prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT jagerelke prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer
AT albatransalaheddin prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer